RxDoctor Payments Data

Yasir Mir

Podiatrist · Westminster, MDNPI 1588684757

Payments from drug & device makers

$912in general payments, 2019–2025

Across 47 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$260
  • Amgen$194
  • AbbVie$109
  • Paratek Pharmaceuticals, Inc.$91
  • Nevro Corp.$52
  • Rikco International, LLC$50
  • plus $157 from 5 others

What the payments were for

  • Food & beverage$88297%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew13$260
Amgen(2 entities)11$194
AbbVie6$109
Paratek Pharmaceuticals, Inc.6$91
Nevro Corp.2$52
Rikco International, LLC2$50
Bioventus LLC2$40
Keswick Pharmaceuticals LLC1$39
Vertex2$33
Melinta Therapeutics, LLC1$28
Kerecis Limited1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$912 in reported general payments places this provider in the 55th percentile of 183 podiatrist providers in Maryland.

See all podiatrist providers in Maryland

Medicare billing

Part B allowed, 2024
$135,548
Medicare patients
686
Services billed
2,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin52$534
Ciclopirox12$376
Amitriptyline Hcl13$174
Pregabalin25$163
Ketoconazole11$137
Cephalexin17$88

Paid to pharmacies, not to this prescriber.

Other podiatrist in Westminster

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →